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TECHNICAL ADVANCE Open Access
Assessing risk of bias: a proposal for a
unified framework for observational studies
and randomized trials
Hendrika J. Luijendijk1* , Matthew J. Page2, Huibert Burger1 and Xander Koolman3
Abstract
Background: Evidence based medicine aims to integrate scientific evidence, clinical experience, and patient values
and preferences. Individual health care professionals need to appraise the evidence from randomized trials and
observational studies when guidelines are not yet available. To date, tools for assessment of bias and terminologies
for bias are specific for each study design. Moreover, most tools appeal only to methodological knowledge to
detect bias, not to subject matter knowledge, i.e. in-depth medical knowledge about a topic. We propose a unified
framework that enables the coherent assessment of bias across designs.
Methods: Epidemiologists traditionally distinguish between three types of bias in observational studies: confounding,
information bias, and selection bias. These biases result from a common cause, systematic error in the measurement or
common effect of the intervention and outcome respectively. We applied this conceptual framework to randomized
trials and show how it can be used to identify bias. The three sources of bias were illustrated with graphs that visually
represent researchers’ assumptions about the relationships between the investigated variables (causal diagrams).
Results: Critical appraisal of evidence started with the definition of the research question in terms of the population of
interest, the compared interventions and the main outcome. Next, we used causal diagrams to illustrate how each
source of bias can lead to over- or underestimated treatment effects. Then, we discussed how randomization, blinded
outcome measurement and intention-to-treat analysis minimize bias in trials. Finally, we identified study aspects that
can only be appraised with subject matter knowledge, irrespective of study design.
Conclusions: The unified framework encompassed the three main sources of bias for the effect of an assigned
intervention on an outcome. It facilitated the integration of methodological and subject matter knowledge in the
assessment of bias. We hope that graphical diagrams will help clarify debate among professionals by reducing
misunderstandings based on different terminology for bias.
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Background
Evidence based medicine requires that individual physi-
cians critically appraise scientific evidence. Guidelines may
offer an overview of the evidence for many clinical situa-
tions, but may not be available or up to date. In addition,
very old treatments, rare diseases and distinct patient
groups are seldom covered in guidelines [1, 2]. In such
cases, physicians will need to appraise the quality of rele-
vant studies and interpret the results accordingly.
Nowadays, medical schools typically provide courses
in the critical appraisal of research findings [3]. Critical
appraisal starts with the definition of the clinical question
in terms of the population of interest, the compared inter-
ventions and the main outcomes. Next, clinical relevance,
reliability and validity of the study results need to be
assessed. A reported effect of the intervention on the out-
come is valid if it accurately reflects the real effect in the
population of interest. If the effect was established with
systematic error it is said to be biased. Risk of bias tools
have been developed to help reviewers appraise studies
in systematic reviews. Examples are the Jadad-score,
Cochrane risk of bias tool, and the Mixed Methods
Appraisal Tool [4–6].
However, the taxonomy of bias and terminology that
is used differs across study designs (ref Schwartz). Differ-
ent types of bias are identified, and even if they are
structurally identical, different terms have been used to
describe them. The lack of a straightforward and con-
sistent framework for bias assessment across designs
complicates bias assessment for health care profes-
sionals, and leads to confusion and unresolved seman-
tic discussions. This is probably why few physicians
assess bias thoroughly as part of their critical ap-
praisals of studies.
In addition, use of subject matter knowledge is com-
mon in the assessment of bias in observational studies,
but far less so in that of randomized trials [7, 8]. Subject
matter knowledge refers to the facts, concepts, theories,
and principles which are specific to a certain medical
topic, e.g. cardiovascular medicine. For example, adjust-
ment for baseline characteristics that are unequally dis-
tributed between treatment groups may be required if
these variables are thought to be predictive of the out-
come on the basis of subject matter knowledge (CON-
SORT) [7, 8]. It is commonly recommended to assess
baseline differences in an observational study, but sel-
dom in a randomized trial [9]. For most trial assessment
tools, the focus is on checking the methodological as-
pects of design and execution, such as randomization
procedures. Less attention is paid to understanding how
the conduct of a trial in conjunction with the clinical
context influenced the study findings. Thus, subject mat-
ter knowledge is indispensable for the assessment of bias
in trial results too.
We propose a unified and simple framework to facili-
tate bias assessment for health care professionals, which
is applicable to observational and experimental designs.
It builds on an understanding of how bias originates and
may be avoided. This knowledge then enables health
professionals to use their subject matter knowledge and
improve the appraisal of the evidence. In addition, stu-
dents and clinicians make use of ‘pre-digested’ evidence
more and more. The framework could also help people
who pre-digest and summarize the evidence to perform
a critical appraisal of the original evidence.
The framework has been accepted in observational
epidemiology and underlines the prevailing taxonomy
for bias. The identified sources of bias are not design
dependent, so our goal was to show how the framework
could be used to evaluate bias in trials, and teach bias
assessment. As the framework stems from the literature
about causal inference, i.e. the process of ascertaining
that an effect is causal and not due to bias, this paper
may also be regarded as an introduction to that litera-
ture [10].
Methods
Epidemiological textbooks typically distinguish three
sources of bias (described in more detail in the Results
section) [11, 12]. First, the exposure and outcome have a
cause in common. This common cause is called a con-
founder in epidemiology. If it is not adjusted for, con-
founding bias occurs. Second, there is systematic
measurement error when (1) the exposure status influ-
ences the measurement of the outcome, (2) the outcome
influences the measurement of the exposure, or (3) a
third factor influences the measurement of both expos-
ure and outcome. Such a measurement error, or (non-
)differential misclassification, leads to information bias,
also known as observation bias or measurement bias.
Third, the exposure and the outcome both determine
whether eligible patients participate in a study and
whether all participants have been included in the ana-
lyses, e.g. a treatment and an adverse effect could have
drop-out in common. In other words, exposure and out-
come have a common effect. The selective drop-out of
patients can result in selection bias.
For each source of bias, a causal diagram can be used
to illustrate its mechanism. A causal diagram displays
how the exposure of interest and the outcome of interest
are associated as a result of the causal relationship of
other variables with the exposure and outcome [10]. As
such, the use of causal diagrams has facilitated identifi-
cation of bias and adjustment for bias in observational
studies [13].
We applied the framework for bias developed in obser-
vational studies to bias assessment in randomized trials.
In the context of randomized trials, the ‘exposure’ is to
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be interpreted as the experimental intervention under
study. The assessment started with the identification of
the causal question and population of interest. Next, we
discussed each source of bias, illustrated it with a causal
diagram, and summarized which study designs and statis-
tical techniques can be applied to minimize it. The sources
of bias also indicated which study results should be
assessed with subject matter knowledge. We have avoided
the use of the terms confounding, information bias, and
selection bias, because their meaning varies across epi-
demiological specialties (see online supplement) [12, 14].
Results
The causal question and population of interest
Risk of bias assessment begins with the identification of
the causal question and population of interest (see
Table 1 and eTable 1). What we usually want to know
is: does intervention I affect outcome O in population P,
and if so how strongly? Or in short: I→O in P?
Population P is the target population to which the
study results should apply. Usually, eligibility criteria de-
termine which patients are included into a trial. These
criteria as a rule do not coincide with the indications
and contra-indications that health professionals take into
account. Therefore, reviewers need to assess which eligi-
bility criteria diminished the representativeness of the
study population for the target population and how this
could have affected the results.
Intervention I is a condition to which a patient can be
exposed or not, e.g. one can be prescribed a drug that
causes weight-loss or not; one cannot receive a certain
weight or not [15]. Placebo is often used as the compari-
son intervention C to control for the natural course of
the disease, be it improvement or deterioration, and the
effect of unspecific treatment elements such as receiving
attention. Pragmatic trials typically test the effectiveness
of a new treatment versus standard treatment. In obser-
vational studies, on the other hand, the outcomes of a
treatment are compared to no-use or another treatment.
A reviewer needs to define a priori what control inter-
vention is clinically relevant.
The effect of an intervention is defined in terms of
clinically relevant, beneficial and harmful outcomes. The
outcomes that trialists chose do not always reflect the
outcomes that are important to patients, for instance a
surrogate outcome such as serum LDL-cholesterol in-
stead of clinical diseases such as myocardial infarction
and stroke. The reviewer needs to determine a priori
which outcomes reflect important health gains ànd
losses. When the causal question has been determined
and a study has been identified that addressed it, the
next step is to assess how the methods could have biased
the reported study results.
Bias due to a common cause
The first possible source of bias is a factor - mostly a pa-
tient characteristic - that affected which intervention
was assigned and influenced the risk of the outcome, in-
dependently. E.g. severity of disease could affect both the
choice for a conventional antipsychotic drug and risk of
death [16]. This is called a common cause [13]. This fac-
tor could explain a co-occurrence (association) between
the intervention and outcome even if the intervention
has no causal relationship with the outcome. Common
causes can be measured or unmeasured.
Table 1 The causal question with 2 × 2 table, OR and RD
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Figure 1 provides a causal diagram of bias due to a
common cause. A causal diagram depicts the investi-
gated effect of an intervention on an outcome (I→O),
and other variables that influence the measured effect.
In Fig. 1, the arrow with the question mark denotes the
causal question (effect) of interest. The unmeasured pa-
tient characteristic C affects intervention I and outcome
O, and it is not taken into account in the analysis (no
box around the variable). The figure shows that even if
there is no effect of I on O, an association between I and
O will be found as a result of the ‘backdoor path’ via
(backwards followed arrow from) I to C and C to O.
Bias due to known and unknown common causes can
be avoided with randomization. Randomization, if per-
formed correctly, ensures that chance determines which
intervention a participant receives. Prognostic patient
characteristics are expected to be equally distributed
across treatment groups. Hence, assuming no other
biases, differences in outcomes between groups can be
attributed to differences in treatment. For randomization
to be effective, the allocation sequence must be truly
random and concealed from those persons responsible
for allocating participants [17]. These prerequisites en-
sure that the persons involved in the allocation cannot
foresee the next allocation and therefore cannot use
knowledge of patient characteristics to (1) change the
treatment or forestall recruitment until the desired inter-
vention comes up (C→ I), or (2) decide not to recruit
the participant into the study at all (see eFigure 1). The
reviewer must assess whether these prerequisites were
met and whether modifications, such as stratified
randomization or blocked randomization with small,
fixed blocks, could have made the next allocation pre-
dictable [18].
A commonly held misconception is that blinding the
persons who provide the intervention is an adequate
way to conceal an allocation. Take for instance an inva-
sive procedure such as surgery, where the person provid-
ing the intervention cannot be blinded. As long as the
recruiter and allocators cannot foresee the next alloca-
tion, this unblinded design will not interfere with the
randomization procedure. Conversely, active and pla-
cebo drug tablets with identical appearance and taste
can blind those involved in giving the treatment. Yet, if
the recruiters or allocators know the allocation
sequence, the allocation can still be (foreseen and) tam-
pered with.
It must be emphasized that even if designed and con-
ducted perfectly, randomization cannot guarantee prog-
nostic comparability of treatment groups. Therefore, the
assessor must evaluate group differences in prognostic
baseline characteristics [8, 19]. According to the CON-
SORT statement, a correctly reported trial will present
the baseline characteristics for all randomized partici-
pants in each intervention group (http://www.consort-
statement.org). Testing the statistical significance of
baseline differences has little value for risk of bias assess-
ment [20, 21]. Sample sizes are often too small for these
tests to be informative at all, and differences that are sta-
tistically insignificant might still cause relevant bias. In
large trials, statistically significant baseline differences
might not always be large enough to be relevant. There-
fore, reviewers must assess whether differences between
groups at baseline could explain the variations in out-
comes irrespective of statistical significance. For in-
stance, in a large trial testing the long-term safety of a
drug for diabetes mellitus, the majority of characteristics
that predict cardiovascular disease and death were dis-
tributed in favor of the drug versus the placebo group.
As the incomparability of groups was not adjusted for,
an underestimated risk of all-cause mortality cannot be
ruled out [22]. When reviewing a set of trials for system-
atic review though, systematic baseline differences across
trials and the distribution of p-values could indicate
failed randomization [23–26].
In trials and observational studies, restriction of the
study population to one stratum of a known common
cause could also be used to avoid bias. If avoidance of bias
due to a known common cause cannot be prevented by
design, this type of bias can be adjusted for in the analyses
if the common cause is measured well. Commonly used
approaches include multivariable regression and propen-
sity scores. Subject matter knowledge is essential to decide
which characteristics need to be adjusted for [13].
Bias due to systematic measurement error
The second type of bias is caused by systematic error in
the measurement of the intervention status or outcome.
Intervention status refers to the study intervention that a
participant receives, that is the active drug or
Fig. 1 I stands for intended intervention, O for outcome, C for a common cause that differs between intervention groups. The arrow with
question mark stands for the causal question (effect) of interest. Boxed nodes indicate variables in the analysis, i.e. C is not adjusted for
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comparison intervention. Systematic measurement error
could be caused by (1) the intervention status influen-
cing the measurement of the outcome, (2) the outcome
influencing the measurement of the intervention status,
(3) or a third factor that causes systematic error in meas-
urement of both the intervention and the outcome sta-
tus. The first type of measurement error is important for
randomized trials. If the outcome assessor (e.g. patient,
health care provider, researcher) is aware of the partici-
pant’s study group at some time during the trial, this
could systematically influence assessments. E.g. an asses-
sor could report or register a more favorable result if ex-
pectations of the new treatment are high, or a less
favorable result if expectations are low. This bias is often
referred to with the term detection bias.
Figure 2 represents the three types of systematic meas-
urement error, with I standing for true intervention, I* for
intervention measured with error, O for true outcome, O*
for outcome measured with error. The graph illustrates
that even if there is no effect of I on O, an association be-
tween I and O will be found as a result of the path of ar-
rows from I to O* and (backwards) O* to O.
The outcome can affect the measurement of the inter-
vention (O→ I*) only if the outcome has already oc-
curred. A prospective design, whereby patients are
recruited prior to the outcome, can be utilized to avoid
this type of measurement error (eTable 1). To circum-
vent the intervention status influencing the outcome
measurement (I→O*), outcome reporters and assessors
need to be blinded to the intervention status. Reviewers
should use subject matter knowledge to assess whether
the method of blinding was (partially) effective. For in-
stance, in spite of the identical appearance of active and
placebo tablets, specific adverse events or the presence
of the health professional providing the intervention
could reveal which intervention was given [27]. Finally, a
third -often unmeasured- factor could systematically
affect the measurement of the intervention (U→ I*), or
the measurement of both treatment and outcome (U→
I* and U→O*).
Measurement error may also be random, i.e. not sys-
tematically related to other variables. Random error in
the intervention status will bias the estimated effect to-
ward the null. This is often referred to as regression di-
lution. Random measurement error in the outcome does
not result in bias. It will, however, lower the statistical
power and increase the width of the confidence interval.
Bias due to a common effect
The third type of bias occurs when both intervention
and outcome determine whether certain eligible patients
are not included in a study, or left out of the analysis
[28]. This common effect, often referred to with the
term selection, drop-out or attrition, can occur before or
during a study. Selections based on intervention and
outcome, whether before or after the start of a study,
will reduce the validity of the study results to the target
population.
A well-known example of bias due to drop-out oc-
curs when trial participants discontinue the experi-
mental treatment due to adverse effects. If disease
deterioration also determines drop-out, an association
between treatment and disease status at the end of
the trial will be found, even if there is no real treat-
ment effect. A lesser-known source of bias arises by
de-selection of patients after a run-in period [29].
This period between screening and randomization is
used to stop medications that are identical or similar
to the experimental drug (wash-out), to administer
placebo treatment in order to identify placebo re-
sponders or compliant patients, or to give the active
treatment to identify intolerant patients. The selection
of patients into the randomized phase of the study is
based on their outcomes during the run-in period,
Fig. 2 I stands for true intervention status, I* for measured intervention status, O for true outcome status, O* for measured outcome status, and U
for a third (usually unmeasured) variable. The arrow with question mark stands for the causal question (effect) of interest. The red arrow signifies
that Intervention I affects measured outcome O*, the green arrow that Outcome O affects measured intervention I*, the purple arrow that a third
factor U affects measured intervention I*, and the blue arrow that a third factor U affects measured intervention I* and outcome O*. Boxed nodes
indicate variables in the analysis
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such as an occurrence of, or a decrease in side-
effects. Treatment response and side effects obtained
in this selected population will not be similar to those
in the population included at screening and may not
represent the target population [30, 31]. The reviewer
should therefore assess whether the results in the se-
lected population can be generalized to the target
population. A similar bias occurs when a cohort study
is based on prevalent instead of first-time (incident)
users [32, 33]. Drop-out during an observational study
due to the effects of the treatment can introduce bias
too: patients with a positive balance between benefi-
cial and harmful reactions are probably overrepre-
sented in the analyzed population.
Bias due to a common effect, or selection, is repre-
sented in Fig. 3. In the graph, intervention I and out-
come Oi at time point i during follow-up lead to
selection S. In other words, patients are selected out of
the study. The effect of I on O was conditioned on S,
which can lead to bias [34].
Bias due to selection (exclusion) can only be avoided if
a study is based on first-time users and complete follow-
up irrespective of treatment or outcome during follow-up
(eTable 1). A valid trial design should not have exclusion
criteria relating to effectiveness of prior (similar) interven-
tions, nor exclude patients during run-in periods based on
their response to active or placebo treatment during this
period. In order to be informative for medical practice, a
trial should include new users that are representative
of patients in daily medical practice. For instance, in
a trial about a drug for influenza, enrichment of the
population with participants who were expected to
show a favorable response, may have obscured the
drug’s lack of effect in North-American adults [35].
This type of selection should be distinguished from
excluding patients with certain contra-indications
from participation (non-eligibility). These patients do
not belong to the population of interest and there-
fore the effect of treatment in these patients is ir-
relevant. An observational study based on incident
users avoids bias due to selection before the start of
the study too.
To assess selection, a flow-chart needs to show drop-
out before and after the start of the study. Reviewers
should use subject matter knowledge to assess how
drop-out could have affected the reported treatment ef-
fect. Preferably, reasons for and proportion of drop-out
should be similar across comparison groups, although
this certainly does not guarantee absence of bias [36]. In
an intention-to-treat analysis, all participants are in-
cluded in the intervention group to which they were al-
located, irrespective of whether they actually received
this intervention or completed the study. Modified ITT-
analysis and per protocol-analysis exclude participants
from the data-analysis [37]. As these are often non-
completers, and completion frequently depends on (the
lack of) efficacy or occurrence of side-effects (see flow-
diagrams of trials), the selection is based on outcomes
and likely to introduce bias.
Combinations of biases
The three types of bias can co-occur. For example, base-
line imbalance between study groups can affect selection
based on treatment and outcome during follow-up. An
example is given in Table 2. To address this, a reviewer
needs to assess the risk of bias due to common causes as
explained earlier.
Discussion
Evidence based medicine requires physicians and other
health professionals to appraise the validity of scientific
evidence. We have applied a framework which is popular
for the assessment of bias in observational studies, to
randomized trials. The framework identifies three
sources of bias and these are independent of study de-
sign. After formulating the causal question, physicians
can assess potential sources of bias using their methodo-
logical and subject matter knowledge. ETable 1 provides
an overview of this approach. As such, our paper com-
plements a previous publication that described the biases
identified in the Cochrane tool for risk of bias with
causal diagrams [38].
A clear advantage of the framework is its consistency and
the use of terminology-free causal diagrams. In addition, it
is robust to (future) modifications of conventional study de-
sign, such as run-in periods in trials, because it covers all
potential sources of bias. Moreover, as the framework facili-
tates consideration of subject matter knowledge, bias
Fig. 3 I stands for treatment status, Oi for intermediate outcome status, Oe for outcome status at endpoint, and S for a common effect
(selection). The arrow with question mark stands for the causal question (effect) of interest. The box around S signifies that exclusion of patients
based on treatment and outcome occurred as a result of the design or the analysis
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assessment within and across study designs may gain more
depth and consistency. The framework could therefore be
useful for reviews covering both randomized trials and ob-
servational studies. A limitation of our approach is that it
requires readers to learn the lexicon of causal diagrams.
We did not discuss protocol deviations in trials. In
most observational studies and in some trials, the ex-
perimental and comparison intervention may not be
static. Content and timing can change during follow-
up, other treatments may be added, patients and
health professionals may not comply well, or the
treatment may be cancelled altogether. If such
changes to the intervention are not permitted accord-
ing to the protocol, they are called protocol devia-
tions. We did not consider protocol deviations as a
cause of bias in the effect of the allocated interven-
tion I on outcome O, provided they are reflective of
routine care [38]. Such deviations are part of and the
result of the allocation (a so-called intermediate ef-
fect). Blinding of patients, caregivers, and attending
health care professionals in trials can avoid some
protocol deviations [17]. Yet, a properly blinded pa-
tient or health care professional might still initiate
additional treatments, change or stop allocated
treatment when the desired effects are not occurring.
Therefore, trial articles usually report whether the
intended experimental versus comparison intervention
yields a treatment effect on average for a group of
patients. Nevertheless, a detailed description and as-
sessment of such protocol deviations, or intermediate
effects, are important aspects of an appraisal. They
might be responsible for the reported effect of the al-
located treatment.
Conclusion
A framework based on three sources of bias has supported
the critical appraisal of observational studies. The three
sources of bias are: a common cause of the intervention
and outcome, a systematic error in the measurement of
the intervention or outcome, and a common effect of the
intervention and outcome. We applied the framework to
randomized trials so that health professionals can use it to
assess risk of bias of such studies. The unified framework
may also be helpful for readers who aim to integrate evi-
dence from both observational studies and randomized
trials in a consistent assessment. Using the framework
stimulates the interpretation of study results in relation to
study design with subject matter knowledge.
Table 2 An example: when baseline differences and attrition are related
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